https://www.selleckchem.com/products/pr-619.html
© 2020 Published by Elsevier B.V. on behalf of Greater Poland Cancer Centre.Cisplatin is a platinum-based first-line drug for treating ovarian cancer. However, chemotherapy tolerance has limited the efficacy of cisplatin for ovarian cancer patients. Research has demonstrated that cisplatin causes changes in cell survival and death signaling pathways through its interaction with macromolecules and organelles, which indicates that investigation into the DNA off-target effects of cisplatin may provide critical insights into the mechanisms u
Like
Comment
Share
